Significance of Semiquantitative Assessment of Preformed Donor-Specific Antibody Using Luminex Single Bead Assay in Living Related Liver Transplantation

DOI PDF XML 被引用文献5件 参考文献13件
  • Atsushi Yoshizawa
    Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
  • Hiroto Egawa
    Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
  • Kimiko Yurugi
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Rie Hishida
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Hiroaki Tsuji
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Eiji Ashihara
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Aya Miyagawa-Hayashino
    Department of Diagnostic Pathology, Kyoto University, Kyoto 606-8507, Japan
  • Satoshi Teramukai
    Division of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Taira Maekawa
    Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
  • Hironori Haga
    Department of Diagnostic Pathology, Kyoto University, Kyoto 606-8507, Japan
  • Sinji Uemoto
    Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

抄録

<jats:p><jats:italic>Aim</jats:italic>. To analyze the risks of preoperatively produced donor-specific antibody (DSA) in liver transplantation.<jats:italic>Methods</jats:italic>. DSA was assessed using direct complement-dependent cytotoxicity (CDC) and anti-human globulin- (AHG-) CDC tests, as well as the Luminex Single Antigen assay. Among 616 patients undergoing blood type identical or compatible living donor liver transplantation (LDLT), 21 patients were positive for CDC or AHG-CDC tests, and the preserved serum from 18 patients was examined to determine targeted Class I and II antigens. The relationships between the mean fluorescence intensity (MFI) of DSA and the clinical outcomes were analyzed.<jats:italic>Results</jats:italic>. Patients were divided into 3 groups according to the MFI of anti-Class I DSA: high (11 patients with MFI > 10,000), low (2 patients with MFI < 10,000), and negative (5 patients) MFI groups. Six of 11 patients with high Class-I DSA showed positive Class-II DSA. Hospital death occurred in 7 patients of the high MFI group. High MFI was a significant risk factor for mortality (). Univariate analysis showed a significant correlation between MFI strength and C4d deposition ().<jats:italic>Conclusions</jats:italic>. HLA Class I DSA with MFI > 10,000 had a significant negative effect on the clinical outcome of patients with preformed DSA in LDLT.</jats:p>

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (13)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ